Ian T. Meredith's most recent trade in Boston Scientific Corp. was a trade of 6,588 Common Stock done at an average price of $43.7 . Disclosure was reported to the exchange on March 28, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Sale of securities on an exchange or to another person at price $ 43.68 per share. | 28 Mar 2022 | 6,588 | 28,082 (0%) | 0% | 43.7 | 287,764 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 1,019 | 34,970 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 1,019 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.17 per share. | 28 Feb 2022 | 300 | 34,670 (0%) | 0% | 44.2 | 13,251 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 6,540 | 6,540 | - | - | Performance Share Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 1,013 | 1,013 | - | - | Deferred Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2022 | 1,013 | 34,249 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 21 Feb 2022 | 298 | 33,951 (0%) | 0% | 42.6 | 12,680 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,250 | 3,750 | - | - | Restricted Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,250 | 32,871 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,037 | 2,076 | - | - | Deferred Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2022 | 1,037 | 33,541 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.83 per share. | 17 Feb 2022 | 367 | 32,504 (0%) | 0% | 42.8 | 15,719 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.55 per share. | 17 Feb 2022 | 305 | 33,236 (0%) | 0% | 42.6 | 12,978 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 12,941 | 12,941 | - | - | Stock Option (Right to Buy) | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 4,525 | 4,525 | - | - | Restricted Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,108 | 31,947 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2022 | 1,108 | 1,108 | - | - | Deferred Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.01 per share. | 15 Feb 2022 | 326 | 31,621 (0%) | 0% | 44.0 | 14,347 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 3,131 | 0 | - | - | Deferred Stock Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 3,131 | 31,758 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.50 per share. | 01 Feb 2022 | 919 | 30,839 (0%) | 0% | 43.5 | 39,977 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,649 | 29,892 (0%) | 0% | 0 | Common Stock | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,649 | 0 | - | - | Performance Share Units | |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.48 per share. | 01 Jan 2022 | 1,265 | 28,627 (0%) | 0% | 42.5 | 53,737 | Common Stock |
| Boston Scientific | Ian T. Meredith | EVP Global Chief Med Officer | Sale of securities on an exchange or to another person at price $ 43.21 per share. | 28 Dec 2021 | 7,018 | 26,243 (0%) | 0% | 43.2 | 303,248 | Common Stock |